Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Creatine for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib, a tyrosine kinase inhibitor (TKI) was examined with the aim of showing its effect on safety comparing a lower dose of 150mg (N=6)…Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial
Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital
Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease
Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) with treadmill training on walking performance and corticomotor excitability in people with Parkinson's disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.